A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00433823 |
Recruitment Status : Unknown
Verified February 2007 by Abant Izzet Baysal University.
Recruitment status was: Recruiting
First Posted : February 12, 2007
Last Update Posted : February 12, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Heart Disease Diabetes Mellitus Non-Coronary Atherosclerotic Disease Hypercholesterolemia | Drug: Atorvastatin, Ezetimibe | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Official Title: | A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis |
Study Start Date : | January 2007 |
Study Completion Date : | January 2008 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Patients in the very high risk group according to the ATPIII guide.
Exclusion Criteria:
- Patients having a major disease involving hepatic, gastrointestinal and endocrinologic diseases other than diabetes.
- Patients having a known muscle disease
- Pregnancy, breast-feeding
- Patients having a history of allergy to statins or ezetimibe
- Nephropathic patients

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00433823
Contact: Mustafa Kanat, MD | +905385448782 | mustafa.kanat@gmail.com |
Turkey | |
Bolu Izzet Baysal School of Medicine | Recruiting |
Bolu, Turkey, 14280 | |
Contact: Mustafa Kanat, MD +905385448782 mustafa.kanat@gmail.com |
Principal Investigator: | Mustafa Kanat, MD | Abant Izzet Baysal University, Bolu Izzet Baysal School of Medicine |
ClinicalTrials.gov Identifier: | NCT00433823 |
Other Study ID Numbers: |
MK-19 |
First Posted: | February 12, 2007 Key Record Dates |
Last Update Posted: | February 12, 2007 |
Last Verified: | February 2007 |
Very low level of LDL Steroid hormones Atorvastatin Ezetimibe Lipoprotein-a |
Heart Diseases Coronary Disease Coronary Artery Disease Myocardial Ischemia Hypercholesterolemia Cardiovascular Diseases Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Vascular Diseases |
Arteriosclerosis Arterial Occlusive Diseases Atorvastatin Ezetimibe Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors |